Ann: COVID ARDS Trial Respiratory Outcomes Presented, page-60

We want SI at conferences reporting these results. We want scientific opinion brought to bear. The politicalization of C-19 costs hundreds of thousands of deaths across the world. Objective scientific debate and information is what matters, still. Probably why the FDA is reviewing its approval of BioGen's Aduhelm - such was the clear scientific communities revolt at the decision.

We want SI out there promoting the incredible CHF results, dangling it under the nose of big Pharma who look upon these conferences with more keeness than us. Novartis in my opinion is probably looking at not only ARDS but also CHF results. Novartis has been one of the most successful companies recently in terms of FDA approvals which include cellular therapies (why I own it as well as MSB).

Remstemcel-L is a very good fit to its existign cellular therapy portfolio, not least of which its successful FDA approved gene therapy Zolgensma (treats genetic spinal muscular atrophy) and more recently FDA and now TGA approved CAR T-cell therapy, Kymriah. I see a very promising partnership coming soon and if its not Novartis (unlikely) take your pick from Roche, Sanofi, Merck, J&J, Pfizer, Elli Lilly, AstraZenica (another I am long given their ventures in gene/cellular therapies), Bristol Myers, Abbvie, Bayer, etc. They will all have experts with eyes on these and the CHF results particularly.